title: Toxic epitheliopathy from a single application of preservative free oxybuprocaine (0.4%) in a patient with Sjogren's syndrome.
abstract: Topical ocular anaesthetic agents are frequently used for ophthalmic diagnosis and surgery. While corneal complications following long-term use or misuse of local anaesthetic solutions have been described, toxic epitheliopathy after a single application of six drops of preservative free oxybuprocaine is rare. In order to increase the awareness of this ocular complication, we report such a case in a patient with Sjogren's syndrome who presented for elective cataract surgery. We outline the mechanisms proposed to explain the ocular toxic effects of oxybuprocaine and discuss the management principles in preventing this complication in the context of Sjogren's syndrome.
authors.affiliation: Department of Medicine, The Northern Hospital, Epping, Victoria, Australia.
authors.forename: Humaira
authors.initials: H
authors.lastname: Ansari
authors.forename: Laurence
authors.initials: L
authors.lastname: Weinberg
authors.forename: Narelle
authors.initials: N
authors.lastname: Spencer
mesh_terms: D060433:Administration, Ophthalmic; D000368:Aged; D000779:Anesthetics, Local / Q000009:adverse effects*; D002387:Cataract Extraction / Q000379:methods; D003316:Corneal Diseases / Q000139:chemically induced*; D019573:Epithelium, Corneal; D005260:Female; D006801:Humans; D011343:Procaine / Q000009:adverse effects / Q000031:analogs & derivatives*; D012859:Sjogren's Syndrome / Q000150:complications*
chemical_list: D000779:Anesthetics, Local; D011343:Procaine; C005298:benoxinate
references.citation: Bull Soc Ophtalmol Fr. 1980 Apr-May;80(4-5):385-7
references.pmid: 7460172
references.citation: Br J Ophthalmol. 2002 Feb;86(2):245-6
references.pmid: 11815357
references.citation: Int Ophthalmol Clin. 1989 Fall;29(3):153-8
references.pmid: 2666331
references.citation: J Cataract Refract Surg. 2007 Nov;33(11):1974-5
references.pmid: 17964407
references.citation: Br J Ophthalmol. 1986 Mar;70(3):202-4
references.pmid: 3954977
references.citation: Curr Opin Ophthalmol. 2012 Jan;23(1):68-72
references.pmid: 22081034
references.citation: Int Ophthalmol. 1984 Jun;7(2):71-3
references.pmid: 6480223
references.citation: Nat Clin Pract Rheumatol. 2006 May;2(5):252-61
references.pmid: 16932698
references.citation: J Ocul Pharmacol. 1988 Fall;4(3):187-94
references.pmid: 3198982
references.citation: Cornea. 2006 Sep;25(8):900-7
references.pmid: 17102664
references.citation: J Am Optom Assoc. 1988 Sep;59(9):701-2
references.pmid: 3183285
references.citation: Ocul Surf. 2009 Apr;7(2 Suppl):S19-20
references.pmid: 19383272
references.citation: CLAO J. 1989 Jul-Sep;15(3):216-8
references.pmid: 2476258
references.citation: Cornea. 2008 Jan;27(1):64-9
references.pmid: 18245969
references.citation: Eye (Lond). 2010 Aug;24(8):1331-7
references.pmid: 20300126
references.citation: Cornea. 1997 Jul;16(4):424-9
references.pmid: 9220240
references.citation: Surv Ophthalmol. 1980 Jul-Aug;25(1):15-30
references.pmid: 6998034
references.citation: Expert Opin Drug Saf. 2007 Nov;6(6):637-40
references.pmid: 17967152
references.citation: Ophthalmologica. 1980;180(4):198-206
references.pmid: 7443191
references.citation: Cornea. 2004 Jul;23(5):527-9
references.pmid: 15220742
references.citation: Ophthalmology. 1990 Aug;97(8):967-72
references.pmid: 2402423
references.citation: Cutan Ocul Toxicol. 2010 Jun;29(2):105-9
references.pmid: 20236030
references.citation: Ophthalmic Physiol Opt. 1998 Sep;18(5):393-400
references.pmid: 10023471
references.citation: Cornea. 2010 Dec;29(12):1412-6
references.pmid: 20847673